Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas

Completed · Not applicable

Conditions studied: High Grade Glioma

In brief

The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.

Key facts

Study ID

NCT02041611

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

20

Starts

2012-07-13

Expected to finish

2015-12-17

Last updated by the study team

2018-06-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be at least 18 years of age.
• Patients must have histologically confirmed new diagnosed high grade glioma by pathology (WHO grade III and IV).
• Patients proposed post-operative treatment plan must include standard radiation and temozolomide.
• Patients must have a Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).
• Patients must be able to provide written informed consent.
• Steroid use is allowed.

You may not qualify if…

• Patients with HIV are excluded.

Where it is running

• Johns Hopkins — Baltimore, Maryland, United States
• Washington University — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.